Selection Criteria for Genetic Assessment of Patients with Familial Melanoma; Sancy A. Leachman, MD, PhD; John Carucci, MD, PhD; Wendy Kohlmann, MS; Kimberly C. Banks, MS; Maryam M. Asgari, MD; Wilma Bergman, MD; Giovanna Bianchi-Scarra, PhD; Teresa Brentnall, MD; Brigitte Bressac-de Paillerets, PharmD; William Bruno, MD; Clara Curiel-Lewandrowski, MD; Femke A. de Snoo, PhD; Tadeusz Debniak, MD; Marie-France Demierre, MD; David Elder, MBChB; Alisa M. Goldstein, PhD; Jane Grant-Kels, MD; Allan C. Halpern, MD; Christian Ingvar, MD, PhD; Richard F. Kefford, MBBS, PhD; Julie Lang, MD, Rona M. MacKie, MD; Graham J. Mann, MBBS, PhD; Kurt Mueller, MD; Julia Newton-Bishop, MD; Hakan Olsson, MD; Gloria M. Peterson, PhD; Susana Puig, MD; Darrell Rigel, MD; Susan M. Swetter, MD; Margaret A. Tucker, MD; Emanuel Yakobson, PhD; John A. Zitelli, MD and Hensin Tsao, MD, PhD.; Journal of the American Academy of Dermatology (JAAD); Volume 61, Number 4.
Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcome of Head and Neck Melanoma Patients; Stanley P. L. Leong, MD; Neil A. Accortt, PhD; Richard Essner, MD; Merrick Ross, MD; Jeffrey E. Gershenwald, MD; Barbara Pockaj, MD; Harald J. Hoekstra, MD; Carlos Garberoglio, MD; Richard L. White, Jr, MD; David Chu, MD; Merrill Biel, MD; Kim Charney, MD; Harold Wanebo, MD; Eli Avisar, MD; John Vetto, MD; Seng-Jaw Soong, PhD; for the Sentinel Lymph Node Working Group; Arch Otolaryngol Head Neck Surg. 2006;132:370-373.
Human Melanoma in Cyclosporine-Immunosuppressed Rats; Goodman, M.M.; McCullough, J.L.; Models in Dermatology, Maiback, H.; Lowe, N. (eds), Basel, Switzerland: Karger, S., Vol. 4, 249-252, 1989.
A Model of Human Melanoma in Cyclosporine-Immunosuppressed Rats; Goodman, M.M.; McCullough, J.L.; Biren, C.A.; Barr, R.J., Journal of Investigative Dermatology, 88(2): 141-144, 1987.